Patents by Inventor Timothy A. Gillespy

Timothy A. Gillespy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KINASE INHIBITOR
    Publication number: 20140142110
    Abstract: The invention is directed to a compound of formula (I): and the prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such a compound has valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: SANOFI
    Inventors: Timothy A. GILLESPY, Elizabeth M. ALLEN, Kin T. YU, Asher ZILBERSTEIN
  • Kinase inhibitor
    Patent number: 8658649
    Abstract: The invention is directed to a compound of formula (I): and the prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such a compound has valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: February 25, 2014
    Assignee: Sanofi
    Inventors: Timothy A. Gillespy, Paul Eynott, Elizabeth M. Allen, Kin T. Yu, Asher Zilberstein
  • Benzimidazoles
    Patent number: 8288425
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: October 16, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry
  • 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
    Patent number: 8193183
    Abstract: The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischem
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: June 5, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Sungtaek Lim, Keith John Harris, David Stefany, Charles J. Gardner, Bin Cao, Ray Boffey, Timothy A. Gillespy, Joacy C. Aguiar, Hazel J. Dyke, Elsa A. Dechaux
  • TREATMENT FOR GLOMERULONEPHRITIS WITH 2-[4-(7-ETHYL-5H-PYRROLO[2,3-B]PYRAZIN-6-YL)PHENYL]PROPAN-2-OL
    Publication number: 20110251219
    Abstract: A treatment for glomerulonephritis, and other renal dysfunctions using a compound of Formula I is disclosed.
    Type: Application
    Filed: June 2, 2011
    Publication date: October 13, 2011
    Applicant: SANOFI
    Inventors: Thomas OLIGINO, Timothy A. GILLESPY, Ramalinga DHARANIPRAGADA, Elizabeth M. ALLEN
  • Azaindoles for inhibiting aurora2 and other kinases
    Patent number: 7943616
    Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: May 17, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
  • TREATMENT FOR OCULAR-RELATED DISORDERS
    Publication number: 20110112101
    Abstract: A treatment for ocular related disorders, such as macular degeneration, and preferably age-related macular degeneration, diabetic retinopathy, and diabetic macular edema is disclosed, using a compound of Formula I.
    Type: Application
    Filed: September 10, 2010
    Publication date: May 12, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Ramalinga DHARANIPRAGADA, Thomas OLIGINO, Chang S. HAHN, Timothy A. GILLESPY, Ellen MATZKIN
  • KINASE INHIBITOR
    Publication number: 20100035884
    Abstract: The invention is directed to a compound of formula (I): and the prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such a compound has valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.
    Type: Application
    Filed: March 10, 2009
    Publication date: February 11, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Timothy A. GILLESPY, Paul EYNOTT, Elizabeth M. ALLEN, Kin T. YU, Asher ZILBERSTEIN
  • Thienopyrazoles
    Publication number: 20070254937
    Abstract: Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).
    Type: Application
    Filed: March 6, 2006
    Publication date: November 1, 2007
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: John Jurcak, Matthieu Barrague, Timothy Gillespy, Michael Edwards, Kwon Musick, Philip Weintraub, Yan Du, Ramalinga Dharanipragada, Ashfaq Parkar
  • 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
    Publication number: 20070244131
    Abstract: The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ische
    Type: Application
    Filed: April 16, 2007
    Publication date: October 18, 2007
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Sungtaek Lim, Keith Harris, David Stefany, Charles Gardner, Bin Cao, Ray Boffey, Timothy Gillespy, Joacy Aguiar, Hazel Dyke, Elsa Dechaux
  • Benzimidazoles
    Publication number: 20060014756
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Application
    Filed: January 4, 2005
    Publication date: January 19, 2006
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Michael Edwards, Paul Cox, Shelley Amendola, Stephanie Deprets, Timothy Gillespy, Christopher Edlin, Andrew Morley, Charles Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir Majid, John Reader, Lloyd Payne, Nawaz Khan, Michael Cherry
  • Azaindoles
    Publication number: 20050267304
    Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Application
    Filed: November 23, 2004
    Publication date: December 1, 2005
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Paul Cox, Tahir Majid, Justine Lai, Andrew Morley, Shelley Amendola, Stephanie Deprets, Christopher Edlin, Charles Gardner, Dorothea Kominos, Brian Pedgrift, Frank Halley, Timothy Gillespy, Michael Edwards, Francois Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel Bezard, Chantal Carrez
  • Azaindoles
    Patent number: 6897207
    Abstract: The invention is directed to physiologically active compounds of general formula (I): and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: May 24, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
  • Benzimidazoles
    Patent number: 6897208
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: May 24, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry
  • Azaindoles
    Publication number: 20040053931
    Abstract: The invention is directed to physiologically active compounds of general formula (I):— 1
    Type: Application
    Filed: June 21, 2002
    Publication date: March 18, 2004
    Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N.A. Bezard, Chantal Carrez
  • Benzimidazoles
    Publication number: 20040048868
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) 1
    Type: Application
    Filed: October 24, 2002
    Publication date: March 11, 2004
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry